55

Phospho-CSF-1R/M-CSF-R (Tyr723) (49C10) Rabbit mAb



Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP, IHC-P	Reactivity: H M	Sensitivity: Endogenous	MW (kDa): 175	Source/Isotype: Rabbit IgG	UniProt ID: #P07333	Entrez-Gene Id: 1436	
Product Usage Information		Application Western Blotting Immunoprecipitation Immunohistochemistry (Paraffin)			Dilution 1:1000 1:200 1:300		
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less thar 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.					
Specificity/Ser	nsitivity	Phospho-CSF-1R/M-CSF-R (Tyr723) (49C10) Rabbit mAb detects endogenous levels of CSF-1R/M-CSF-R only when phosphorylated at tyrosine 723. The antibody does not cross-react with related active protein tyrosine kinases.					
Source / Purifi	cation	Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr723 of human CSF-1R/M-CSF-R.					
Background		Macrophage-colony stimulating factor (M-CSF, CSF-1) receptor is an integral membrane tyrosine kinase encoded by the <i>c-fms</i> proto-oncogene. M-CSF receptor is expressed in monocytes (macrophages and their progenitors) and drives growth and development of this blood cell lineage (1-3). Binding of M-CSF to its receptor induces receptor dimerization, activation, and autophosphorylation of cytoplasmic tyrosine residues used as docking sites for SH2-containing signaling proteins (4). There are at least five major tyrosine autophosphorylation sites. Tyr723 (Tyr721 in mouse) is located in the kinase insert (KI) region. Phosphorylated Tyr723 binds the p85 subunit of PI3 kinase as well as PLCy2 (5). Phosphorylation of Tyr809 provides a docking site for Shc (5). Overactivation of this receptor can lead to a malignant phenotype in various cell systems (6). The activated M-CSF receptor has been shown to be a predictor of poor outcome in advanced epithelial ovarian carcinoma (7) and breast cancer (8).					
Background R	eferences	1. Stanley, E.R. et al. (1978) <i>Nature</i> 274, 168-70. 2. Byrne, P.V. et al. (1981) <i>J Cell Biol</i> 91, 848-53. 3. Bourette, R.P. and Rohrschneider, L.R. (2000) <i>Growth Factors</i> 17, 155-66. 4. Novak, U. et al. (1996) <i>Oncogene</i> 13, 2607-13. 5. Bourette, R.P. et al. (1997) <i>EMBO J</i> 16, 5880-93. 6. Morley, G.M. et al. (1999) <i>Oncogene</i> 18, 3076-84. 7. Toy, E.P. et al. (2001) <i>Gynecol Oncol</i> 80, 194-200. 8. Maher, M.G. et al. (1998) <i>Clin Cancer Res</i> 4, 1851-6.					
Species Reacti	vity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).					
Western Blot E	Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.					
Applications K	ey	W: Western Blotting IP: Immunoprecipitation IHC-P: Immunohistochemistry (Paraffin)					
Cross-Reactivi	ty Key	H: Human M: Mouse					
Trademarks ar	nd Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.					
Limited Uses	 All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information. d Uses Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CS the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer' terms and conditions that are in addition to, or different from, those contained herein, unless 					resentative of CST, s. Any Customer's	

separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.